Trippbio Announces Close Of Enrollment In The Phase 2 Study Of Pancytovir In Patients With Mild-To-Moderate COVID-19

  • Ralph Tripp
Period8 Sep 2022

Media coverage

3

Media coverage

  • TitleTrippbio Announces Close Of Enrollment In The Phase 2 Study Of Pancytovir In Patients With Mild-To-Moderate COVID-19
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date8/09/22
    PersonsRalph Tripp
  • TitleTrippBio Announces Close of Enrollment in the Phase 2 Study of PanCytoVir™ in Patients with Mild-to-Moderate COVID-19
    Media name/outletEIN Presswire
    Country/TerritoryUnited States
    Date8/09/22
    PersonsRalph Tripp
  • TitleTrippbio Announces Close Of Enrollment In The Phase 2 Study Of Pancytovir In Patients With Mild-To-Moderate COVID-19
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date8/09/22
    PersonsRalph Tripp